Literature DB >> 3947035

A clinicopathological study of 323 patients with oligodendrogliomas.

C L Ludwig, M T Smith, A D Godfrey, V W Armbrustmacher.   

Abstract

All patients with oligodendrogliomas (554) from the repository of the Armed Forces Institute of Pathology were retrospectively analyzed. The pathological diagnosis was confirmed in 323 patients and each case was graded according to a previously established grading system. The clinical features of these 323 verified cases of oligodendroglioma are presented, analyzed, and compared with findings in previous studies. There is a significant age skew according to tumor grade, with 68% of patients with grade A tumors under 40 years and 83% of patients with grade D tumors over 40 years of age. Headache was the most common symptom, followed by seizure, visual loss, papilledema, paralysis, and dementia. No symptoms showed a statistically significant correlation with tumor grade. However, tumor grading allowed significant prognostic statements to be made. Attention is drawn to several often neglected symptoms of oligodendrogliomas: ataxia, hemorrhage, stroke, and cerebrospinal fluid spread. This is, to our knowledge, the largest clinicopathological study of oligodendrogliomas to date.

Entities:  

Mesh:

Year:  1986        PMID: 3947035     DOI: 10.1002/ana.410190104

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

1.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.

Authors:  Ali Chahlavi; Andrew Kanner; David Peereboom; Susan M Staugaitis; Paul Elson; Gene Barnett
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

Review 3.  Cerebellopontine angle oligodendroglioma in a child: first case report.

Authors:  J R Ellenbogen; S Perez; C Parks; D Crooks; C Mallucci
Journal:  Childs Nerv Syst       Date:  2013-09-22       Impact factor: 1.475

4.  Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: comparison with established biomarkers and preoperative UCSF low-grade scoring system.

Authors:  Shirley Abraham; Nan Hu; Randy Jensen
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

5.  Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.

Authors:  A Boiardi; A Silvani; A Pozzi; M Farinotti; L Fariselli; G Broggi; A Salmaggi
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

6.  Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.

Authors:  Rudolf A Kristof; Georg Neuloh; Volkmar Hans; Martina Deckert; Horst Urbach; Uwe Schlegel; Matthias Simon; Johannes Schramm
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

7.  Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

Review 8.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

9.  Aggressive oligodendroglioma predicted by chromosome 10 restriction fragment length polymorphism analysis. Case study.

Authors:  J K Wu; R D Folkerth; Z Ye; B T Darras
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

10.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.